TAKHZYRO DIN 02564483
Status: Marketed
Holder: TAKEDA CANADA INC
Health Canada record
| Active ingredient(s) | LANADELUMAB 300 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Subcutaneous |
|---|
| Schedule | PRESCRIPTION; SCHEDULE D |
|---|
| Class | Human |
|---|
| ATC | B06AC05 LANADELUMAB |
|---|
| Original market date | 20-Apr-2026 |
|---|
| Current status date | 20-Apr-2026 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Takeda Canada Inc. — licence 101769, currently licensed, last inspection rating C (2026-02-24).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing LANADELUMAB
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02480948 | TAKHZYRO | TAKEDA CANADA INC | Solution | LANADELUMAB 300 MG | Marketed |
| 02505614 | TAKHZYRO | TAKEDA CANADA INC | Solution | LANADELUMAB 300 MG | Marketed |
| 02566257 | TAKHZYRO | TAKEDA CANADA INC | Solution | LANADELUMAB 150 MG | Approved |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 36715 | 2026-01-09 | Supplement to a New Drug Submission (SNDS) | New presentation. Updates to the Product Monograph |
Request a quote for TAKHZYRO
How to read a Canadian DIN record